(19)

(11)

EP 4 770 757 A1

(12)

(43) Date of publication: 08.07.2026 Bulletin 2026/28 (21) Application number: 24786189.1 (22) Date of filing: 03.09.2024

(51) International Patent Classification (IPC):  A61P 35/00(2006.01) C07D 413/12(2006.01) A61K 31/423(2006.01) (52) Cooperative Patent Classification (CPC): C07D 413/12; A61P 35/00 (86) International application number: PCT/US2024/045046 (87) International publication number: WO 2025/050125 (06.03.2025 Gazette 2025/10)

(84) Designated Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR Designated Extension States: BA Designated Validation States: GE KH MA MD TN (30) Priority: 01.09.2023 US 202363580106 P 19.06.2024 US 202463661725 P (71) Applicant: Immvention Therapeutix, Inc. Research Triangle Park, NC 27709 (US)	(72) Inventors: CLARK, Ryan Reaearch Triangle Park, NC 27709 (US) GALLOVIC, Matthew Reaearch Triangle Park, NC 27709 (US) (74) Representative: Barrès, Sarah et al Novo Nordisk A/S Corporate Patents Novo Allé 2880 Bagsværd 2880 Bagsværd (DK)